FibroGen rises after company begins mid-stage study for prostate cancer therapy

** Shares of drug developer FibroGen FGEN.O rise 2.3% to $12.25

** Company says it has began testing its experimental therapy, FG-3246, in patients with metastatic castration-resistant prostate cancer in a mid-stage study

** The condition is an advanced stage of prostate cancer in which the cancer has spread to distant parts of the body and continues to grow and progress despite hormonal therapy aimed at lowering testosterone

** The trial will also evaluate how well FG-3180 works as a diagnostic and predictive PET imaging agent, which uses the same CD46-targeted antibody as FG-3246

** Company expects results from the interim analysis of a 75-patient mid-stage study in the second half of 2026

** Including session's moves, stock up 7.5% YTD